John Cijiang He MD PhD
Professor of Medicine, Division Chief of Nephrology, Icahn School of Medicine
Join to View Full Profile
Mount Sinai HospitalOne Gustave L Levy PlaceNew York, NY 10029
Phone+1 212-241-4568
Dr. He is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. John He is a nephrologist based in New York, NY, specializing in areas including general nephrology, diabetic kidney disease, glomerular disease, and dialysis. He completed his residency in Internal Medicine at SUNY Downstate Health Sciences University and a fellowship in Nephrology at the Icahn School of Medicine at Mount Sinai. As a Professor of Medicine and Attending Physician at Mount Sinai since 2003, his recent research includes publications on topics such as mechanisms of diabetic kidney disease, development of new therapies for kidney fibrosis, and podocyte biology and injury. He also conducts clinical trials, including new therapy for FSGS and kidney fibrosis.
Education & Training
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalFellowship, Nephrology, 2000 - 2003
SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 1997 - 2000
Shanghai Jiao Tong University School of MedicineClass of 1986
Certifications & Licensure
NY State Medical License 2000 - 2028
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Nephrology
Clinical Trials
- Evaluation of Gut Bacteria in Patients With Polycystic Kidney Disease Start of enrollment: 2013 Dec 01
Publications & Presentations
PubMed
- APOL1-risk alleles modulate T-cell receptor signaling to promote allograft rejection.John Pell, E M Tanvir, Zeguo Sun, Irene Chernova, Anand Reghuvaran
The Journal of Clinical Investigation. 2026-06-09 - ALDH1A1 is a potential novel target for treatment of ADPKD.Liwen Zhang, John Cijiang He
Kidney International. 2026-04-01 - 1 citationsCurrent Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease.Shuai Hu, Kyung Lee, John Cijiang He, Ying Fan
Clinical Journal of the American Society of Nephrology. 2026-03-10
Journal Articles
- Podocyte-Specific Loss of Krüppel-like Factor 6 Increases Mitochondrial Injury in Diabetic Kidney DiseaseSandeep K Mallipattu, John C He, Diabetes Care
- Novel Therapeutics Identification for Fibrosis in Renal Allograft Using Integrative Informatics ApproachJohn Cijiang He, Barbara Murphy, Bernd Schroppel, Madhav C Menon, Nature
Grant Support
- EYA1 as a novel regulator of HIV-induced end stage kidney diseaseICAHN SCHOOL OF MEDICINE AT MOUNT SINAI2026–2029
- EYA1 as a novel regulator of HIV-induced end stage kidney diseaseICAHN SCHOOL OF MEDICINE AT MOUNT SINAI2026–2029
- EYA1 as a novel regulator of HIV-induced end stage kidney diseaseICAHN SCHOOL OF MEDICINE AT MOUNT SINAI2026–2029
- KLF2 is a novel endoprotective target for DKDICAHN SCHOOL OF MEDICINE AT MOUNT SINAI2024–2029
- Lead optimization of Tyro3 agonists as a novel therapy for glomerular diseaseJAMES J PETERS VA MEDICAL CENTER2024–2028
Professional Memberships
- Member
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
